Annals of Surgical Oncology

, Volume 15, Issue 3, pp 945–946 | Cite as

Reexcisions in Breast-Conserving Surgery for Breast Cancer: Can They Be Avoided?

Breast Oncology


  1. 1.
    O’Sullivan MJ, Li T, Freedman G, Morrow M. The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol 2007;14:3133–40PubMedCrossRefGoogle Scholar
  2. 2.
    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45PubMedCrossRefGoogle Scholar
  3. 3.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRefGoogle Scholar
  4. 4.
    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087–106PubMedGoogle Scholar
  5. 5.
    Sacchini V, Pinotti JA, Barros AC, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg 2006;203:704–14PubMedCrossRefGoogle Scholar
  6. 6.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRefGoogle Scholar
  7. 7.
    Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399–405PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004;11:127–9PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRefGoogle Scholar
  11. 11.
    Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16–24PubMedGoogle Scholar
  13. 13.
    Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 1990;116:307–13CrossRefGoogle Scholar
  15. 15.
    Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRefGoogle Scholar
  16. 16.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRefGoogle Scholar
  17. 17.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1PubMedGoogle Scholar
  18. 18.
    Bollet MA, Sigal-Zafrani B, Mazeau V. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 2007;82:272–80. Erratum in: Radiother Oncol 2007;83:215PubMedCrossRefGoogle Scholar
  19. 19.
    Fatouros M, Baltoyiannis G, Roukos DH. The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Woman With BRCA1 or BRCA2 Mutations. Ann Surg Oncol 2007;[Epub ahead of print], doi:10.1245/s10434-007-9612-4 Google Scholar
  20. 20.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115–23CrossRefGoogle Scholar
  21. 21.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMedCrossRefGoogle Scholar
  23. 23.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRefGoogle Scholar
  24. 24.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  1. 1.3rd Department of SurgeryUniversity of AthensAthensGreece

Personalised recommendations